NextCell Pharma (Sweden) Insiders
| NXTCL Stock | SEK 1.69 0.01 0.60% |
NextCell Pharma employs about 15 people. The company is managed by 6 executives with a total tenure of roughly 35 years, averaging almost 5.0 years of service per executive, having 2.5 employees per reported executive. Breaking down NextCell Pharma's management performance can provide insight into the firm performance.
| Sofie Jansson Insider Marketing Director |
| Mathias Svahn Insider Founder CEO |
NextCell |
NextCell Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.1747) % which means that it has lost $0.1747 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2957) %, meaning that it generated substantial loss on money invested by shareholders. NextCell Pharma's management efficiency ratios could be used to measure how well NextCell Pharma manages its routine affairs as well as how well it operates its assets and liabilities.NextCell Pharma Workforce Comparison
NextCell Pharma AB is regarded second in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 300. NextCell Pharma holds roughly 15.0 in number of employees claiming about 5% of stocks in Biotechnology industry.
NextCell Pharma AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. NextCell Pharma AB Price Series Summation is a cross summation of NextCell Pharma price series and its benchmark/peer.
NextCell Pharma Notable Stakeholders
A NextCell Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NextCell Pharma often face trade-offs trying to please all of them. NextCell Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NextCell Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Sofie Jansson | Marketing Director | Profile | |
| Mathias Svahn | Founder CEO | Profile | |
| Anders MSc | Chairman | Profile | |
| Edvard Smith | Medical Director | Profile | |
| Patrik Fagerholm | Chief Officer | Profile | |
| Lindsay Davies | Chief Officer | Profile |
About NextCell Pharma Management Performance
The success or failure of an entity such as NextCell Pharma AB often depends on how effective the management is. NextCell Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NextCell management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NextCell management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden. NextCell Pharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 10 people.
Please note, the imprecision that can be found in NextCell Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NextCell Pharma AB. Check NextCell Pharma's Beneish M Score to see the likelihood of NextCell Pharma's management manipulating its earnings.
NextCell Pharma Workforce Analysis
Traditionally, organizations such as NextCell Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NextCell Pharma within its industry.NextCell Pharma Manpower Efficiency
Return on NextCell Pharma Manpower
| Revenue Per Employee | 372.6K | |
| Revenue Per Executive | 931.5K | |
| Net Loss Per Employee | 2.3M | |
| Net Loss Per Executive | 5.8M |
Additional Tools for NextCell Stock Analysis
When running NextCell Pharma's price analysis, check to measure NextCell Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCell Pharma is operating at the current time. Most of NextCell Pharma's value examination focuses on studying past and present price action to predict the probability of NextCell Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCell Pharma's price. Additionally, you may evaluate how the addition of NextCell Pharma to your portfolios can decrease your overall portfolio volatility.